TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02878408

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
Study: NCT01148524

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: No Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
Study: NCT00970073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1000 mg PO/IV BID for up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 1000 mg PO/IV BID for up to 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 1000 mg PO/IV BID for up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus 3-8
Description: Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus 3-8
Description: Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus 8-12
Description: Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
Study: NCT00053573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg to 40 mg/kg qow
Study: NCT02380144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh orange fruit and pasteurized fruit juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh orange fruit and pasteurized fruit juice
Study: NCT01501331

Intervention type: DEVICE
Intervention: CRTD or ICD (Energen)
Description: RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
Study: NCT03545100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control therapy
Description: scapular muscle progressive resistive exercise(PRE)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular physical therapy
Description: transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular physical therapy
Description: transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
Study: NCT01373489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Case Management
Description: The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
Study: NCT00292396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti IL-12 monoclonal antibody/ABT-874
Description: Please see Arm Description for intervention description and details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti IL-12 monoclonal antibody/ABT-874
Description: Please see Arm Description for intervention description and details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti IL-12 monoclonal antibody/ABT-874
Description: Please see Arm Description for intervention description and details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti IL-12 monoclonal antibody/ABT-874
Description: Please see Arm Description for intervention description and details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti IL-12 monoclonal antibody/ABT-874
Description: Please see Arm Description for intervention description and details.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 doses
Study: NCT04652440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofequencey or microwave ablation
Description: The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
Study: NCT01083485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets
Description: Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
Study: NCT00562029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal Bypass
Description: Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
Study: NCT02746172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant with in-situ audiometry
Study: NCT04970784

Intervention type: OTHER
Intervention: Activities of Daily Living (ADL) questionnaire (The Katz index )
Description: For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30.

Intervention type: OTHER
Intervention: Activities of Daily Living (ADL) questionnaire (The Katz index )
Description: For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30.
Study: NCT04099407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
Study: NCT01230723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-Eluting-Stent
Description: due randomization everolimus-eluting-stent will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-Eluting-Stent
Description: due randomization zotarolimus-eluting-stent will be implanted
Study: NCT01896336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Hemitartrate
Description: Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Hemitartrate
Description: Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD
Study: NCT04222231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood-flow restriction resistance training
Description: Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical resistance training
Description: Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
Study: NCT02319512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: ChiczaTM organic chewing gum 6 pieces a day

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Glucose
Description: 12ml glucose solution (13,6g) per day
Study: NCT03836703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Feroglobin single daily use
Description: Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feroglobin twice daily dose
Description: Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Study: NCT02954627

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary Supplement: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study: NCT01680965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)
Study: NCT03252119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow humidified oxygen therapy
Description: application of high flow humidified oxygen therapy at 2l/kg/min
Study: NCT04111809

Intervention type: BIOLOGICAL
Intervention: Blood and urine collection
Description: collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
Study: NCT00697359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Description: The ILR will be implanted subcutaneous following standard surgical procedure.
Study: NCT02233569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
Description: Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
Description: Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventralight ST implant
Study: NCT01999751

Intervention type: DEVICE
Intervention: MRI Scan
Description: Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
Study: NCT01148524

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rMenB+OMV-NZ
Description: Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
Study: NCT00292591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vitamin D3)
Description: randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
Study: NCT02233569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETHICON PHYSIOMESH®
Study: NCT00292591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
Study: NCT01613794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg od
Study: NCT02746419

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vessix
Description: Renal denervation using radio-ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessix
Description: Renal denervation using radio-ablation
Study: NCT04220775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01019915

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT
Description: Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
Study: NCT04980209

Intervention type: DEVICE
Intervention: ultrasound evaluation
Description: According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
Study: NCT01676870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1x4 aerobic interval training
Description: endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4x4 aerobic interval training
Description: endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional moderate training
Description: moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
Study: NCT02392442

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
Study: NCT04147286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: 12 weeks of 40 mg atorvastatin therapy per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Identical placebo
Study: NCT03931824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
Study: NCT01484041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
Study: NCT01973569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously to match denosumab
Study: NCT00427947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine/placebo
Description: Continuous sciatic nerve bloc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine/placebo
Description: Continuous sciatic nerve bloc
Study: NCT02906904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Intervention
Description: 24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Intervention
Description: 24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS